SCHEMBL6498253

SCHEMBL6498253

NC(C=O)c1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.43
TDO2 P48775 2/20 0.43
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
GABBR2 O75899 1/20 0.36
GABBR1 Q9UBS5 1/20 0.36
AOC3 Q16853 2/20 0.34
ALDH1A1 P00352 2/20 0.33
LMNA P02545 1/20 0.33
ALPG P10696 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20495038 1.00 IDO1 (0.43) IDO1TDO2HDAC3HDAC4HDAC1
SCHEMBL13131486 1.00 IDO1 (0.43) IDO1TDO2HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL3809942 0.98 IDO1 (0.45) IDO1TDO2HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL13738816 0.85 TYR (0.33)
Hydrochloric Acid SCHEMBL2035158 0.78 DRD1 (0.32)
Hydrochloric Acid SCHEMBL3388587 0.78 DRD1 (0.32)
SCHEMBL18155699 0.77 IDO1 (0.40) IDO1TDO2HDAC3HDAC4HDAC1
SCHEMBL7193441 0.76 ESR1 (0.42) IDO1TDO2ALDH1A1LMNA
SCHEMBL540045 0.76 HTR2A (0.39) ALDH1A1
SCHEMBL4736322 0.76 ADRB2 (0.50) IDO1TDO2HDAC4HDAC7HDAC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2978425-A2 FACTOR XIa INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-02-03 EP disclosed
EP-2970298-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2016-01-20 EP disclosed
EP-2935271-A1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS Bristol-Myers Squibb Company (US) 2015-10-28 EP disclosed
WO-2014164467-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2014-10-09 WO disclosed
WO-2014160592-A2 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-10-02 WO disclosed
WO-2014100533-A1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-06-26 WO disclosed
WO-2005016883-A2 ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF ICOS CORPORATION (US) 2005-02-24 WO disclosed
EP-1406897-A2 COMPOUNDS SmithKline Beecham plc (GB) 2004-04-14 EP disclosed
WO-2003002559-A2 PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST SMITHKLINE BEECHAM P.L.C. (GB) 2003-01-09 WO disclosed